PT - JOURNAL ARTICLE AU - YASUHIRO ITO AU - NAOYOSHI ONODA AU - TAKUMI KUDO AU - HIROO MASUOKA AU - TAKUYA HIGASHIYAMA AU - MINORU KIHARA AU - AKIHIRO MIYA AU - AKIRA MIYAUCHI TI - Sorafenib and Lenvatinib Treatment for Metastasis/Recurrence of Radioactive Iodine-refractory Differentiated Thyroid Carcinoma AID - 10.21873/invivo.12350 DP - 2021 Mar 01 TA - In Vivo PG - 1057--1064 VI - 35 IP - 2 4099 - http://iv.iiarjournals.org/content/35/2/1057.short 4100 - http://iv.iiarjournals.org/content/35/2/1057.full SO - In Vivo2021 Mar 01; 35 AB - Background/Aim: Radioactive iodine-refractory differentiated thyroid carcinoma (RR-DTC) has been treated with multi-kinase inhibitors (MKIs), e.g., sorafenib (SOR) and lenvatinib (LEN). We analyzed the outcomes of RR-DTC patients who underwent SOR or LEN treatment at Kuma Hospital. Patients and Methods: We enrolled 21 and 18 patients treated with SOR and LEN, respectively. Results: The incidence of partial response in the LEN group was significantly higher than that in the SOR group. Serum thyroglobulin significantly decreased from the beginning of treatment to 1 month later in the LEN group (not in the SOR group). The neutrophil-lymphocyte ratio (NLR) was significantly decreased at 1 month later in both groups. An NLR ≥3 at the start of MKI treatment had a prognostic impact. Conclusion: For RR-DTC, LEN could be more effective than SOR, at least in the short term. The first-line drug should be selected based on other factors (e.g., adverse events, patient background).